BioLineRx Ltd. BLRX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
BioLineRx Ltd. (BLRX) is a healthcare company listed in the US with a market value of about $6M. In fiscal year 2025 it had revenue of $1M and net income of -$2M, a net margin of -171.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -87%.
About BioLineRx
BioLineRx is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $29M | $5M | $0 | $0 | — | — | — | — | — |
| Net income | -$2M | -$9M | -$61M | -$25M | -$27M | -$30M | -$25M | -$23M | -$24M | -$16M |
| Free cash flow | -$8M | -$44M | -$23M | -$26M | -$24M | -$23M | -$23M | -$24M | -$21M | -$15M |
| EPS (diluted) | $-0.41 | $-1.85 | $-12.18 | $-5.01 | $-5.43 | $-6.03 | $-5.11 | $-4.61 | $-4.89 | $-3.18 |
| Net margin | -171.7% | -31.9% | -1262.8% | — | — | — | — | — | — | — |
| ROIC | -35.8% | -89.9% | -239.8% | -44.0% | -27.6% | -65.0% | -53.0% | -40.4% | -37.5% | -36.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does BioLineRx pay a dividend?
Not currently.
Is BioLineRx a good stock to buy?
We do not give buy or sell advice. BioLineRx scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.